ARTIFICIAL beta-CELLS AND METHODS OF USE THEREOF

A technology of granule and membrane fusion, applied in the field of treatment of diseases, can solve the problems of elusive replication and so on

Pending Publication Date: 2020-06-30
NORTH CAROLINA STATE UNIV
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although multi-compartmental assemblies have been created to recreate the hierarchical architecture of cells for the delivery of drug mixtures or cascade reactions (Boyer, C. et al., ACS Nano 1, 176-182 (2007); Wong, B. et al. , Adv.Mater.23, 2320-2325 (2011); Marguet, M. et al., A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • ARTIFICIAL beta-CELLS AND METHODS OF USE THEREOF
  • ARTIFICIAL beta-CELLS AND METHODS OF USE THEREOF
  • ARTIFICIAL beta-CELLS AND METHODS OF USE THEREOF

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0135] Materials and general methods.

[0136] Material. All lipids, including egg phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), 1,2- Dioleoyl-sn glycerol-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) and 1,2-dioleoyl-sn - Glycerol-3-Phosphatidylethanolamine - Lissamine - Rhodamine B, all purchased from Avanti Polar Lipids, Inc. All peptides were synthesized by Biochem Co., Ltd. (Shanghai, China). All DNA was purchased from DNA Technologies, Inc. (Coralville, IA, USA). Cholesterol, glucose oxidase, catalase, gramicidin A, methoxypolyethylene glycol maleimide (mPEG-Mal, molecular weight = 5000), phenylmethylsulfonyl fluoride (PMSF), Dialkyl β-D-maltoside (DDM) and 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) were purchased from Sigma-Aldrich. Human recombinant insulin was purchased from Life Technology. Anti-Glucose Transporter 2 antibody was purchased fr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent;and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 559,909 filed September 18, 2017, the disclosure of which is expressly incorporated herein by reference in its entirety. technical field [0003] The disclosure herein relates to granules, methods for delivering therapeutic agents, and methods for treating diseases such as diabetes. Background technique [0004] Pancreatic β cells dynamically regulate insulin secretion to maintain blood glucose homeostasis. Destruction or dysfunction of these cells leads to type 1 and type 2 diabetes, a family of chronic diseases that currently affect more than 415 million people in the world (Rorsman, P., Annu. Rev. Physiol. 75, 155-179( 2013); Yu, J. et al., Proc. Natl Acad. Sci. USA 112, 8260-8265 (2015); Ohkubo, Y. et al., Diabetes. Res. Clin. Pract. 28, 103-117 (1995)). Insufficient glycemic control due to loss of β-cell function can lead to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K47/69A61K9/51A61K31/00A61K31/04A61K31/44
CPCA61K9/127A61K47/6911A61K38/28A61K47/42
Inventor 顾臻陈昭伟
Owner NORTH CAROLINA STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap